New York, NY (PRWEB) February 16, 2013
On February 16, Voices Against Brain Cancer (VABC) responds to new research that sheds light on the origins of glioblastoma multiforme, the deadliest and most common form of brain cancer.
An article from Discover Magazine discusses recent findings that show that “glioblastoma can be triggered when two genes fuse, [and] a targeted therapy to reverse the disease may be a step closer.”
There are approximately 10,000 cases of glioblastoma each year, according to the article, and about three percent of those are caused by a merger of two specific genes. Researchers believe that a similar merger in genes could be the cause of an even more significant number of yearly diagnoses of the deadly disease. “The mergers occur during DNA replication, when matching segments of otherwise disparate genes mistakenly pair up. The fused gene in turn produces abnormal proteins that destabilize entire chromosomes, resulting in aggressive cancers,” states the article.
Oncologists are already developing a new treatment based on these findings. The new experimental drug targets abnormal proteins produced by the DNA merger that result in aggressive brain cancer. After testing the drug on lab mice, researchers say they saw treated mice live twice as long as untreated ones.
The new findings suggest that established therapies “have largely failed because they are aimed at the wrong target,” says the article.
“Glioblastoma is one of the hardest forms of cancer to treat,” says Michael Klipper, Chairman of Voices Against Brain Cancer (VABC). “We're constantly chasing after definitive answers. However, those who are paying attention know that we've recently seen a lot of big steps forward for brain cancer research,” explains Klipper. “Hopefully this means that we are getting closer to establishing future treatment protocols that are both safe and effective.”
VABC has a wide variety of initiatives in place for brain cancer research, awareness and support. The organization’s research grants fund cutting-edge research programs that will have a monumental impact on the diagnosis and treatment of brain cancer. VABC currently funds research at several esteemed institutions such as Brookhaven National Laboratory, Cleveland Clinic, Columbia, Cornell, Duke, Harvard, John Hopkins, Memorial Sloan-Kettering and Yale, to name a few.
VABC's mission is to find a cure for brain cancer by advancing scientific research, increasing awareness within the medical community and supporting patients, their families and caregivers afflicted with this devastating disease.
For press inquiries, please contact: 5W Public Relations.